A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes (NCT04786262)
A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-880 in Subjects Who Have Type 1 Diabetes Mellitus With Impaired Hypoglycemic Awareness and Severe Hypoglycemia
🩺 Plain-English Summary (8th-Grade Level)
This study will evaluate the safety, tolerability and efficacy of VX-880 infusion in participants with Type 1 diabetes (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.
Who can join: Review the eligibility criteria below.
Location: City of Hope — Duarte, California
Age range: 18 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (29 Sites)
Showing the first 25 of 29 sites.
- City of Hope — Duarte, California
- University of California San Francisco — San Francisco, California
- UHealth Diabetes Research Institute — Miami, Florida
- Northwestern Organ Transplant Center — Chicago, Illinois
- University of Chicago — Chicago, Illinois
- Johns Hopkins University — Baltimore, Maryland
- Massachusetts General Hospital — Boston, Massachusetts
- Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania
- University of Pittsburgh Medical Center Montefiore — Pittsburgh, Pennsylvania
- Baylor Scott and White Research Institute — Dallas, Texas
- VCU Medical Center, Richmond — Richmond, Virginia
- University of Wisconsin — Madison, Wisconsin
- University of Alberta, Edmonton — Edmonton,
- McGill University Health Centre — Montreal,
- Toronto General Hospital (TGH) — Toronto,
- Vancouver General Hospital — Vancouver,
- CHU Lille — Lille,
- Centre de recherche en Biomédecine de Strasbourg — Strasbourg,
- Dresden Center for Islet Transplantation — Dresden,
- IRCCS Ospedale San Raffaele — Milan,
- Leiden University — Leiden,
- Oslo University Hospital — Oslo,
- King Abdullah International Medical Research Center (KAIMRC) - Riyadh - Endocrinology — Riyadh,
- King Faisal Specialist Hospital & Research Centre - Riyadh - Endocrinology — Riyadh,
- Hopiteaux Universitaires de Geneve — Geneva,
📞 Contact the Study Coordinator
Phone: (617) 341-6777
Email: medicalinfo@vrtx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Diabetes Mellitus, Type 1
- Testing an Integrated Care Model Trial — Atlanta, Georgia
- Safety of ENC-201-CED ENCRT — Toronto, Ontario
- Teplizumab in Pediatric Stage 2 Type 1 Diabetes — San Francisco, California
- Allogenic Islet Cell Transplantation — Chicago, Illinois
- Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells — Charleston, South Carolina
- Feasibility Study of Extended Wear Insulin Infusion Set Options During Home Use in People With Type 1 Diabetes — Stanford, California
Explore by condition: All Diabetes Mellitus, Type 1 clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.